Clinical trial NCT04871425
Conditions: Abortion in First Trimester Pain, Procedural Opioid Use
Sponsor: University of Washington
Start date: 2021-04-27; Completion date: 2021-10-14
Enrollment: 110 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Ketamine is commonly used for procedural sedation and analgesia. It is widely used for trauma cases in the emergency department and is considered a superior agent in the outpatient setting due to its lack of respiratory and cardiovascular depression. In chronic opioid users, ketamine decreases acute pain and reduces postoperative opioid consumption. Few studies have examined the use of ketamine for surgical abortions. Previous studies found significant rates of emergence phenomena; however, this can be prevented if a benzodiazepine is given at the same time. Ketamine deserves further study to determine whether it is an acceptable alternative to a standard opioid-based regimen for surgical abortion. Our primary objective is to compare patient satisfaction after surgical abortion among patients receiving IV ketamine versus IV fentanyl for procedural sedation. Our secondary objectives include postoperative pain, additional pain medication used, and postoperative opioid use after the procedure. Our hypothesis is that ketamine will provide similar patient satisfaction and reduce postoperative opioid use. This will be a randomized controlled noninferiority clinical trial of 84 women receiving either IV ketamine with IV midazolam or IV fentanyl with IV midazolam for outpatient one day surgical abortions up to 13, 6/7 weeks gestation. Both groups will receive a standardized paracervical block and additional pain medication as needed. Our study has the potential to introduce IV ketamine as a satisfactory medication for outpatient surgical abortions. Ketamine may decrease the need for IV fentanyl, reduce postoperative opioid use, and may prove to be a superior analgesic for chronic opioid users.

Detailed description:
First-trimester surgical abortions are one of the most common outpatient procedures worldwide. Although abortion is a quick procedure, most patients still report at least moderate pain.1 Most providers use a paracervical block plus intravenous (IV) moderate sedation with fentanyl (38%) or oral medication (33%). A recent trial comparing IV fentanyl to placebo among participants who also received the paracervical block found a 1-point difference in pain on an 11-point scale. The authors questioned the benefit of this reduction in pain in light of fentanyl's various side effects including nausea and drowsiness, the requirement for additional monitoring and resuscitative equipment, and need for naloxone in case of overdose.

Due to our nation's opioid crisis, there has been growing interest in identifying a non-opioid medication to provide safe, short term, satisfactory pain control during first trimester outpatient surgical abortions. Ketamine is commonly used for procedural sedation and analgesia, and it also reduces postoperative pain. It acts primarily as an N-methyl-D-aspartate receptor antagonist but has some opioid receptor activity. It is widely used for trauma cases and acute pain crises, and is considered a superior agent in the outpatient setting due to its lack of respiratory and cardiovascular depression. Few studies have examined ketamine for surgical abortions. Most studies found improvement when compared to the paracervical block or remifentanil. Our study's primary outcome was to determine if ketamine was noninferior in terms of patient satisfaction with anesthesia to fentanyl for procedural sedation for outpatient first trimester surgical abortions.

Arms: arm 1: Participant will receive 2mg IV midazolam and 0.2-0.5mg/kg IV ketamine over 2 minutes, which can be repeated q5 minutes until appropriate analgesia is achieved. arm 2: Participant will receive 2mg IV midazolam and 0.5-1mcg/kg IV fentanyl over 2 minutes, which can be repeated q5m until appropriate analgesia is achieved.
Interventions: intervention 1: Ketamine intervention 2: Fentanyl
Intervention descriptions: intervention 1: IV ketamine intervention 2: IV fentanyl

Protocol documents:
ICF_001.pdf: 
 
Version Number 2 
5/11/2021 
 
1
Cover Page 
 
TITLE: Ketamine versus Fentanyl for Surgical Abortions: A Randomized Controlled Noninferiority 
Trial 
 
NCT NUMBER: 00012218 
 
DOCUMENT DATE: 2/2/2022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
Version Number 2 
5/11/2021 
 
2
UNIVERSITY OF WASHINGTON CONSENT FORM 
Ketamine versus Fentanyl for Surgical Abortions: A Randomized Controlled 
Noninferiority Trial 
 
Researchers’ statement 
We are asking you to be in a research study. The purpose of this consent form is to give you the 
information you will need to help you decide whether to be in the study or not. Please read the 
form carefully. You may ask questions about the purpose of the research, what we would ask 
you to do, the possible risks and benefits, your rights as a volunteer, and anything else about the 
research or this form that is not clear. When we have answered all your questions, you can 
decide if you want to be in the study or not. This process is called “informed consent.” We will 
give you a copy of this form for your records. A description of this clinical trial will be available 
on https://www.clinicaltrials.gov, as required by U.S. Law. This Web site will not include 
information that can identify you. At most, the Web site will include a summary of the results. 
You can search this Web site at any time.  
 
KEY INFORMATION ABOUT THIS STUDY 
The investigators wish to determine if ketamine is a satisfactory alternative to fentanyl for pain 
control during first trimester abortions. Your consent is being sought to participate in this 
research, and your participation is voluntary. If you consent to participate in this research, you 
will be involved for 2 weeks after your procedure. We will ask you to complete an eligibility 
form, a preprocedure survey, a postprocedure survey, a followup survey 1 day after your 
procedure, and a follow up survey 1 week after your procedure. Participating in this study has the 
potential benefit of receiving a more satisfactory pain medication during your procedure. The 
risks include breach of confidentiality, or someone finding out about your participation in the 
study, or potentially receiving a less satisfactory pain medication during your procedure. If you 
choose not to participate in this study, your anesthetist will determine the safest pain medication 
to give you, which may be advantageous to you. If either of these medications would be unsafe 
for you, you will not be enrolled in this study.  
 


 
Version Number 2 
5/11/2021 
 
3
PURPOSE OF THE STUDY 
Although abortions are one of the most common procedures performed worldwide, many 
different techniques are used for pain control throughout the world and within the United States. 
Most clinics use a combination of intravenous (IV) sedation and local anesthesia. Most providers 
are comfortable using IV fentanyl; however, this is not a good option for everyone. IV ketamine 
has been widely used for trauma cases in the emergency department and decreases pain in patient 
with opioid use disorder. Few studies have examined the use of IV ketamine for surgical 
abortions. The purpose of this study is to examine the satisfaction with pain control when using 
IV ketamine versus IV fentanyl.  
 
STUDY PROCEDURES 
Participation in this study will require a pre-procedure survey, a post-procedure survey, and 2 
follow up surveys at home lasting 1-week total. If you choose to participate in this study, before 
your procedure, you will fill out a survey about yourself and your medical and sexual history. 
You can refuse to answer any of these questions if they make you uncomfortable. This survey 
will take approximately 10 minutes and will be given to you while you are waiting for your 
procedure. You will then be randomly assigned to receive either IV ketamine or IV fentanyl, 
similar to flipping a coin. Only your anesthetist will know which medication you receive; your 
provider will not know. If you need additional pain medication during your procedure, the 
anesthetist will administer additional pain medication and this information will be collected from 
your medical record to use for the study. After your procedure, you will fill out another survey 
asking about your experience with the pain medication you received. This survey will take 
approximately 5 minutes. The next day, you will receive a text message with a link to another 
survey that will ask you about your mood, pain, satisfaction with the pain medication you 
received, and use of pain medications. This survey will take approximately 10 minutes. One 
week after your procedure, you will receive another text message with a link to a final survey 
that will ask about your mood, pain, constipation, and use of pain medications. This survey will 
take approximately 10 minutes. You may receive up to 4 additional text messages if you have 
not responded to the survey within 48 hours. These text messages will be sent through a third 
party web service and will not contain any identifying information about your abortion or 
participation in this study.   


 
Version Number 2 
5/11/2021 
 
4
 
RISKS, STRESS, OR DISCOMFORT 
There is a risk of loss of confidentiality about your participation in the study from receiving text 
messages about the followup surveys for this study; however, the text messages will not contain 
any information about you or the procedure. Answering some of the questions in the surveys 
may make you uncomfortable. You do not have to answer any questions that make you 
uncomfortable. Survey answers will be stored with your subject ID only and will not be 
associated with your name. A breach of confidentiality may result in negative psychological 
effects due to people knowing about your abortion. However, we will ensure confidentiality of 
any identifying information. By enrolling in our study, there is the potential that you may receive 
a drug that is unsafe for you. However, we have strict inclusion criteria and eligibility 
questionnaires that will mitigate this risk. Additionally, the anesthetist who consents you as per 
routine clinic practice will have the ability to determine if you are ineligible for this study for 
other reasons and always has the ability to give medications outside of the protocol if necessary 
for your safety.  
 
RISKS OF MEDICATIONS 
The possible risks of receiving IV ketamine include: 
• 
Nausea 
• 
Vomiting 
• 
Dizziness 
• 
Vision changes 
• 
Drowsiness 
• 
Confusion 
• 
Bad dreams 
The possible risks of receiving IV fentanyl include: 
• 
Intense happiness or excitement 
• 
Confusion 
• 
Drowsiness 
• 
Nausea 
• 
Vision changes 


 
Version Number 2 
5/11/2021 
 
5
• 
Constipation 
• 
Difficulty moving 
• 
Hallucinations 
• 
Addiction 
• 
Losing consciousness 
• 
Low blood pressure 
• 
Difficulty breathing 
All participants will receive midazolam per standard clinical care, which may help reduce some 
of the side effects of the medications. In addition to these risks, there may be unanticipated side 
effects. If you experience any side effects that endanger your safety, your anesthetist and 
provider will treat you appropriately. If you experience any of these side effects after you leave 
the clinic, you should contact Jennifer Chin at 206.221.9074.  
 
ALTERNATIVES TO TAKING PART IN THIS STUDY 
Taking part in this study is completely voluntary. It will not affect the care you receive at Cedar 
River Clinics or the University of Washington in any way. You will receive appropriate 
anesthesia as determined by your anesthetist. You or you anesthetist can choose either or both 
medications. You may also leave this study at any time.  
 
BENEFITS OF THE STUDY 
By participating in this study, you will help expand the knowledge of IV ketamine for pain 
control in outpatient surgical abortions in the first trimester. This knowledge will help us take 
better care of patients who choose to have surgical abortions in clinics and potentially give 
patients a non-opioid alternative for pain control. You may potentially receive a more 
satisfactory pain medication by participating in this study, or you may not benefit directly from 
participating in this study.  
 
SOURCE OF FUNDING 
The study team and the University of Washington is receiving financial support from the 
Society of Family Planning. 
 


 
Version Number 2 
5/11/2021 
 
6
CONFIDENTIALITY OF RESEARCH INFORMATION 
Data will be confidential. Your study data will be linked to your name via a subject ID number. 
All of the information you provide will be confidential. However, if we learn that you intend to 
harm yourself or others, we are mandated reporters and must contact emergency services to 
ensure your safety and the safety of others. Government or university staff sometimes review 
studies such as this one to make sure they are being done safely and legally. If a review of this 
study takes place, your records may be examined. The reviewers will protect your privacy. The 
study records will not be used to put you at legal risk of harm. A description of this clinical trial 
will be available on http://www.clinicaltrials.gov, as required by U.S. Law.  This Web site will 
not include information that can identify you. At most, the Web site will include a summary of 
the results. You can search this Web site at any time. 
Using Your Data in Future Research 
The information that we obtain from you for this study might be used for future studies. We may 
remove anything that might identify you from the information. If we do so, that information may 
then be used for future research studies or given to another investigator without getting 
additional permission from you. It is also possible that in the future we may want to use or share 
study information that might identify you. If we do, a review board will decide whether or not 
we need to get additional permission from you.  
 
OTHER INFORMATION 
You may refuse to participate and you are free to withdraw from this study at any time 
without penalty or loss of benefits to which you are otherwise entitled. If you wish to withdraw, 
please contact the researcher listed on page 1 of this consent form. You will be compensated for 
your time and effort to participate in this study. After you complete your first follow up survey at 
home, you will receive a $25 gift card within 1 week. After you complete your second and final 
follow up survey at home, you will receive another $25 gift card within 1 week. This will total 
$50 in gift cards in total. Depending on your cell phone plan, you may incur charges related to 
the use of text message surveys. If you would prefer not to receive text messages, you may 
request an emailed survey link instead. 


 
Version Number 2 
5/11/2021 
 
7
 
A copy of the consent form will be emailed to you at an email address that you provide. It 
will be a “PDF” document. Most computers already have PDF viewer software installed, which 
will allow you to open, read, or print the consent form. The email we send you will include a link 
to PDF viewer software (such as Adobe Acrobat Reader) in case your computer doesn’t already 
have it. If you would prefer to receive a paper copy of the consent form at no cost to you, please 
contact the researcher listed on page 1 of this consent form. 
 
RESEARCH-RELATED INJURY 
It is important that you promptly tell the researchers if you believe that you have been injured 
because of taking part in this study. You can tell the researcher in person or call her at the 
number listed at the top of this form. This number is monitored 24 hours a day. If you are injured 
as a result of being in this study, necessary medical treatment will be offered at a UW Medicine 
facility. The costs of the treatment may be billed to you or your health insurance just like other 
medical costs, or it may be covered by the UW’s discretionary Human Subjects Assistance 
Program (HSAP), depending on a number of factors.  The researcher may request HSAP 
coverage by following established procedures. If you wish to request HSAP coverage yourself, 
contact the researcher or the UW Human Subjects Division at hsdinfo@uw.edu or 206-543-
0098. You may also call collect to the UW Human Subjects Division at 206-221-5940 if you do 
not otherwise have access to a telephone. Ask the researcher if you would like information about 
the limits and conditions of the HSAP. The UW does not normally provide any other form of 
compensation for injury. However, the law may allow you to seek payment for injury-related 
expenses if they are caused by malpractice or the fault of the researchers. You do not waive any 
right to seek payment by signing this consent form. We will bill your health insurance for 
treating problems that result from your surgical abortion or from standard clinical care. If you 
have no health insurance or your insurance refuses to pay, we will bill you. 
 
SUBJECT’S STATEMENT 
This study has been explained to me. I volunteer to take part in this research. I understand that 
individual research results will not be released to me. I have had a chance to ask questions. If I 
have questions later about the research, or if I have been harmed by participating in this study, I 
can contact one of the researchers listed on the first page of this consent form. If I have questions 


 
Version Number 2 
5/11/2021 
 
8
about my rights as a research subject, I can call the Human Subjects Division at 206.543.0098 or 
call collect at 206.221.5940. I give permission to the researchers to use my medical records as 
described in this consent form. I will receive a copy of this consent form. 
Printed name of subject: _________________________ 
Signature of subject: ____________________________ 
Date: ________________________________________ 
Copies to: Researcher, Subject 
 
 

Prot_SAP_002.pdf: 
Cover Page 
 
TITLE: Ketamine versus Fentanyl for Surgical Abortions: A Randomized Controlled Noninferiority 
Trial 
 
NCT NUMBER: 04871425  
 
 
DOCUMENT DATE: 3/25/2021 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROJECT SUMMARY   
Ketamine is commonly used for procedural sedation and analgesia. It is widely used for trauma cases in 
the emergency department and is considered a superior agent in the outpatient setting due to its lack of 
respiratory and cardiovascular depression. In chronic opioid users, ketamine decreases acute pain and 
reduces postoperative opioid consumption. Few studies have examined the use of ketamine for surgical 
abortions. Previous studies found significant rates of emergence phenomena; however, this can be 
prevented if a benzodiazepine is given at the same time. Ketamine deserves further study to determine 
whether it is an acceptable alternative to a standard opioid-based regimen for surgical abortion. Our 
primary objective is to compare patient satisfaction after surgical abortion among patients receiving IV 
ketamine versus IV fentanyl for procedural sedation. Our secondary objectives include postoperative pain, 


additional pain medication used, and postoperative opioid use after the procedure. Our hypothesis is that 
ketamine will provide similar patient satisfaction and reduce postoperative opioid use. This will be a 
randomized controlled noninferiority clinical trial of 84 women receiving either IV ketamine with IV 
midazolam or IV fentanyl with IV midazolam for outpatient one day surgical abortions up to 13, 6/7 
weeks gestation. Both groups will receive a standardized paracervical block and additional pain 
medication as needed. Our study has the potential to introduce IV ketamine as a satisfactory medication 
for outpatient surgical abortions. Ketamine may decrease the need for IV fentanyl, reduce postoperative 
opioid use, and may prove to be a superior analgesic for chronic opioid users.  
 
 
PROPOSAL NARRATIVE 
Background 
First-trimester surgical abortions are one of the most common outpatient procedures worldwide. 
Approximately 46 million are performed annually, with over 600,000 occurring in the United States.1 
Although it is a quick procedure, 78%–97% of patients still report at least moderate pain.1 Many different 
techniques have been used for pain control during this procedure. From most common to least common, 
providers use the paracervical block (PCB), oral anxiolytics, moderate sedation or general anesthesia, and 
newer research has found promise in auricular acupuncture.2,3 Most providers use intravenous moderate 
sedation (38%) or the PCB with an oral medication (33%).2 In a recent survey, most clinics who use local 
anesthesia supplement with IV fentanyl in doses of 50-100 mcg. A recent trial comparing IV fentanyl to 
placebo found a 1-point difference in pain on an 11-point scale. However, the authors question the benefit 
of this reduction in pain in light of fentanyl’s various side effects including dizziness and drowsiness, the 
requirement for additional monitoring and resuscitative equipment, and need for an antidote in case of an 
overdose.4  
 
Due to our nation’s opioid crisis and a recent focus on non-opioid alternatives, there has been growing 
interest in identifying a medication other than fentanyl that will provide safe, short term, satisfactory pain 
control during first trimester outpatient surgical abortions. Ketamine is commonly used for procedural 
sedation and analgesia, and it also reduces postoperative pain.5 It acts primarily as an N-methyl-D-
aspartate receptor antagonist but has some opioid receptor activity.6 It is widely used for trauma cases in 
the emergency department, sickle cell crises, and opioid-induced hyperanalgesia, and is considered a 
superior agent in the outpatient setting due to its lack of respiratory and cardiovascular depression.7-10 In 
patients with opioid use disorder, ketamine decreases acute and perioperative pain and can reduce 
postoperative opioid consumption.11-14 Few studies have examined ketamine for surgical abortions. Most 
studies found improvements in pain control when compared to the paracervical block or remifentanil.15,16 


Previous studies found significant rates of emergence phenomena, where patients experience nightmares 
or delirium when awakening from ketamine anesthesia, which has likely limited its widespread use in the 
abortion setting; however, this can be prevented if a benzodiazepine is given at the same time.17,18 An 
ongoing study in Canada is examining ketamine for first trimester surgical abortions with a primary 
outcome of postoperative pain between oral morphine, IV fentanyl, and IV ketamine.19 Ketamine 
deserves further study to determine whether it is an acceptable alternative to a standard opioid-based 
regimen for surgical abortion. 
 
Research Objectives 
Primary objective: To determine if satisfaction with anesthesia among patients receiving ketamine is non-
inferior compared to satisfaction among those receiving fentanyl for outpatient first trimester surgical 
abortions.  
 
Secondary objectives: 
1. To determine if postoperative pain differs among participants receiving ketamine versus fentanyl.  
2. To determine the amount of additional pain medication needed in those receiving ketamine versus 
fentanyl. 
3. To assess provider satisfaction with anesthesia for those receiving ketamine versus fentanyl. 
4. To compare the time to discharge between those receiving ketamine versus fentanyl. 
5. To compare pain on postoperative day 1 for those receiving ketamine versus fentanyl. 
6. To assess the amount of opioid used 1 week postoperatively for those receiving ketamine versus 
fentanyl. 
Hypothesis: Satisfaction with anesthesia among individuals receiving ketamine will be non-inferior to 
satisfaction among those receiving fentanyl during first trimester abortions.  
 
Outcomes: 
1. Primary outcome: patient satisfaction with anesthesia measured using the Iowa Satisfaction with 
Anesthesia Scale (ISAS) measured either 30 minutes postoperatively or at time of discharge if 
less than 30 minutes 
2. Secondary outcomes:  
a. Postoperative pain using a 100mm visual analog scale (VAS) measured either 30 minutes 
postoperatively or at time of discharge if less than 30 minutes 
b. Additional pain medication administered by anesthetist after standard loading dose for 
each arm 


c. Provider satisfaction with anesthesia of patient during procedure on a 100mm VAS 
d. Time from completion of procedure to discharge 
e. Pain on postoperative day 1 measured on a 100mm VAS using a text message link to an 
online RedCap survey  
f. Patient satisfaction with anesthesia on postoperative day 1 measured using ISAS  
g. Quantity of opioids used 1 week postoperatively using a text message link to an online 
RedCap survey 
h. Adverse events and severe adverse events 
 
Overall research question: Is ketamine a satisfactory alternative to fentanyl for pain control during first 
trimester outpatient surgical abortions? 
 
Additional data to be collected: 
1. Sociodemographic and clinical data: age, race/ethnicity, gravidity, parity, gestational age, prior 
vaginal delivery, prior surgical abortion, level of menstrual symptoms, anxiety or depression, 
previous or current use of opioids. 
 
Design and Methods 
Research Design and Methodological Approach 
This will be a randomized controlled noninferiority trial of IV ketamine versus IV fentanyl for pain 
control during first trimester surgical abortions. We will recruit 84 participants from a local abortion 
clinic with two locations. Our team has an established relationship with this clinic, CRC, with multiple 
University of Washington Complex Family Planning faculty members and three fellows currently 
providing care at this clinic, and several successful research collaborations in the past.  
 
Study Population 
Participants for this study are women 14 years or older, recruited from CRC, who present for an induced 
surgical termination of pregnancy up to 13 weeks 6 days gestation. This upper gestational age limit was 
selected because misoprostol is utilized for cervical ripening starting at 14 weeks per clinic protocol, and 
pretreatment with misoprostol may alter procedural pain and satisfaction. 
 
The following inclusion and exclusion criteria apply: 
Inclusion Criteria: 
- 
Aged 14 years or older  


- 
Voluntarily requesting surgical pregnancy termination 
- 
Intrauterine pregnancy up to 13 weeks 6 days by transabdominal or transvaginal ultrasound 
performed on day of procedure 
- 
Eligible for suction curettage 
- 
English or Spanish speaking 
- 
Able and willing to give informed consent and agree to terms of the study 
 
Exclusion Criteria: 
- 
Age less than 14 years 
- 
Reaspiration procedure or failed medication abortion  
- 
Early pregnancy loss 
- 
Alcohol use disorder or acute alcohol intoxication  
- 
Currently incarcerated 
- 
Gestational age 14 weeks or more 
- 
Requesting a specific pain regimen  
- 
Premedication with misoprostol 
- 
Contraindications or allergies to ketamine or fentanyl  
ISAS is a validated tool used to measure satisfaction with monitored anesthesia care itself, not the 
perioperative experience.20 Participants answer 11 questions with scores ranging from -3 to +3, and the 
mean score gives a quantitative measure of a patient’s satisfaction. Previous studies have shown 0.6 on 
ISAS to be a significant difference, and that scores have a standard deviation of 0.87.21 Thus, we 
calculated our sample size with a noninferiority margin of 0.6, standard deviation of 0.87, 80% power, 
one-sided type 1 error of 0.025, and inflated this number by 10% to account for potential dropout for a 
total sample size of 84 patients. We will compare mean scores using the student’s t-test. All outcomes 
after discharge will be collected using text message prompts, which will link to a REDCap survey. 
Alcohol use disorder and acute alcohol intoxication will be defined by the DSM-5 criteria and will be 
determined by the study personnel prior to consenting the patient.  
Subject recruitment and allocation 
On the day of the procedure, eligible women will be introduced to the study by research personnel who 
have been trained in the recruitment process at the study site. Recruitment will continue until the required 
sample size of 84 is attained. Patients will be introduced to the study after the decision to undergo a 
surgical abortion has been made. Patients will be informed that they will receive the same care whether or 


not they choose to participate in the study, and that they can remove themselves from the study at any 
point in time. 
 
After establishing that all inclusion criteria are met, patients will receive detailed information about the 
study and if interest continues, sign a UW IRB-approved written consent available in English and 
Spanish. Patients will be allowed to ask all questions about the study prior to enrollment and will be asked 
to briefly summarize the study prior to signing the consent form to ensure comprehension. The abortion 
providers will be experienced attending physicians and fellows (including the study investigators). A 
recruitment log will track the number of patients who were approached about the study and will note how 
many were excluded or declined entry. While there is no minimum gestational age required for study 
participation, patients must have a documented measurable intrauterine gestational sac per standard 
practice at the study site.  
 
All providers will have received information about this study prior to enrollment. Providers will be read a 
verbal consent form and will give verbal consent to participate in the study.  
 
Randomization and allocation concealment 
Just prior to starting the procedure, after written consent to participation in the study has been obtained, 
the subject will be randomized to a treatment group using a predetermined computer-generated blocked 
randomization (block size of 6) and will be allocated using sequentially numbered, opaque, sealed 
envelopes. Patients will concurrently be assigned a unique study ID number. Study staff at UW will 
generate the randomization sequence and prepare the envelopes. The randomization scheme linking 
patients to their unique study ID will be kept in a password-protected excel spreadsheet. Study 
investigators will not have access to this password. For data analysis, a member of the study team 
responsible for randomization concealment will provide the primary investigator with blinded allocation 
information.  
 
Description of the drugs and devices to be studied 
Clinicians including certified registered nurse anesthetists (CRNAs), advanced registered nurse 
practitioners (ARNPs), and abortion providers will be able to provide additional medications if needed. 
 
Ketamine: 
Ketamine is a nonbarbiturate dissociative anesthetic. It acts primarily as a noncompetitive N-methyl-D-
aspartate and glutamate receptor antagonist and a partial agonist on opiate mu receptors. It can be used 


alone or as an adjunct to other medications for pain relief or as a pre-anesthetic to other general anesthetic 
agents. Due to its unique properties, ketamine can be used during painful procedures by causing sedation 
and analgesia. It is an ideal medication for patients with bronchospasm due to its bronchodilatory 
properties. It is metabolized by the liver and has a half-life of approximately 45 minutes. The initial dose 
is 1-4.5 mg/kg administered intravenously over 60 seconds with almost immediate onset of action. When 
given in high doses, negative emergence phenomena may occur. This can be prevented by 
coadministration of a benzodiazepine, such as midazolam. Allergic reactions to ketamine are rare. 
Common side effects include nausea, vomiting, dizziness, diplopia, drowsiness, dysphoria, confusion, and 
negative emergence phenomena. Ketamine is contraindicated in those who are hypersensitive to the drug, 
chronic alcoholics or acutely alcohol-intoxicated patients, and in patients with schizophrenia.5 Because 
alcohol acts as a synergist to ketamine’s physiologic effects, the combination of ketamine and alcohol can 
potentially be lethal. For the purposes of this study, patients will receive an initial loading dose of 200-
500mcg/kg IV ketamine over 2 minutes, which will then be repeated q5m until appropriate analgesia is 
achieved. The total amount of ketamine given will not exceed 30mg.  
 
Fentanyl: 
Fentanyl is a strong synthetic opioid. It acts primarily as a mu-selective opioid receptor agonist and can 
also activate delta and kappa receptors. It can be used as a sedative, to treat chronic pain, or as 
premedication for procedures. It is similar to morphine but 50-100 times more potent. It is metabolized by 
the liver. The initial dose for analgesia is usually 100 mcg IV. When given in high doses, fentanyl can 
cause respiratory depression leading to arrest, and overdose can be lethal. Naloxone, an opioid drug 
antagonist, can be used to treat a fentanyl overdose. Common side effects include euphoria, confusion, 
drowsiness, nausea, visual disturbances, and constipation. Severe side effects include dyskinesia, 
hallucinations, delirium, addiction, loss of consciousness, and hypotension. Fentanyl is contraindicated in 
patients who are hypersensitive or intolerant to the drug, have respiratory depression or obstructive 
airway disease, or in patients with liver failure.22 For the purpose of this study, patients will receive an 
initial loading dose of 0.5-1mcg/kg IV fentanyl over 2 minutes, which will then be repeated q5m until 
appropriate analgesia is achieved.  
 
Admission procedure 
Following determination of eligibility and collection of demographic information by research personnel 
and completion of informed consent, participants will complete a pre-procedure survey to collect baseline 
characteristics and baseline pain and be randomized into a specific arm of the study and be concurrently 
assigned a participant ID number as described above. The document linking the participant ID number to 


the subject’s name will be stored in a password-protected document separate from the document linking 
the randomization to the participant ID number. The anesthetist will open the next available sequentially 
numbered, opaque, sealed envelope, which contains the participant ID number and the study allocation, 
either IV ketamine (study arm) or IV fentanyl (control arm). The anesthetist will thus be the only 
individual to know the participant’s randomization. All others will be blinded. Per clinic standard, all 
participants will receive premedication with 500 mg oral naproxen and 4 mg ODT ondansetron prior to 
their procedure. All patients receiving sedation are asked to be NPO preoperatively. All participants in 
this study will receive 2mg IV midazolam, which is standard clinical practice. If the participant is 
assigned to the ketamine arm, the anesthetist will follow the ketamine administration protocol as detailed 
above. If the participant is assigned to the fentanyl arm, the anesthetist will follow the fentanyl 
administration protocol as detailed above. Per protocol, the provider will communicate with the 
anesthetist if more pain medication is needed, such as if the participant is moving, reporting pain, or 
otherwise not tolerating the procedure. These additional medications will be documented and collected as 
secondary outcomes.  
 
The procedures will be performed in accordance with the study design which is consistent with standard 
clinical procedure. Paracervical block will be administered with 20mL of 1% plain lidocaine: 2mL 
injected into the anterior cervical lip prior to tenaculum placement, 8mL injected paracervically 
superficially at 2, 4, 8 and 10 o’clock, and the remaining 10mL injected intracervically at 4 and 8 o’clock. 
Next, the provider will serially dilate the cervix to the number of mm equivalent to or one mm more than 
the patient’s gestational age in weeks (i.e. to 8 mm at 8 weeks 0 days to 8 weeks 6 days gestation), and a 
corresponding size suction cannula will be used. At our study site, up to a gestational age of 9 weeks 6 
days, manual vacuum aspiration is generally performed, and beyond this gestational age electric vacuum 
aspiration is more common. 
 
In order to minimize variability in procedures, all procedures are performed by an experienced provider 
(attending physician or complex family planning fellow). No medical students or residents will perform 
procedures for study participants. The research personnel will collect pre-procedure information from the 
participant in a private counseling or waiting room. After the procedure, either at time of discharge (if less 
than 30 minutes) or at 30 minutes (if not yet discharged), research personnel will assess the participant’s 
level of postoperative pain on a 100mm VAS and have the participant complete the ISAS. The anesthetist 
will record additional pain medications given outside of the study protocol. The provider will be asked 
their level of satisfaction with the participant’s anesthesia on a 100mm VAS. The research personnel will 
note time to discharge after procedure completion and any adverse events. Per clinic standard, all patients 


will be discharged with 30 tablets of naproxen 500mg and 5 tablets of oxycodone 5mg. Patients are 
instructed to use their naproxen first for pain and to use the oxycodone only for breakthrough pain.  
 
Follow up procedure 
All patients will be contacted via text message on postoperative day 1 with a unique link to a REDCap 
survey assessing their pain on a 100mm VAS and their satisfaction using ISAS. Satisfaction will be asked 
again to compare responses on the day of the procedure versus on postoperative day 1. Previous research 
has shown significant variation in what people remember about their procedure, and thus assessing 
satisfaction on postoperative day 1 is equally as important as assessing on the day of the procedure.23 
They will then be sent a text message on postoperative day 7 with a unique link to a separate REDCap 
survey assessing their pain on a 100mm VAS and how much opioids they required in the week following 
the procedure. As patients are instructed to use oxycodone only for breakthrough pain, this is another 
measure of pain and will give us more information about the severity of their pain.  
 
Criteria for discontinuation 
Patients may choose to withdraw from the trial at any time on their own request for any reason; the reason 
for withdrawal will be recorded in detail. No further data will be obtained from the patient once 
withdrawal occurs. Any data obtained up to this point will be analyzed in accordance with intention to 
treat analysis. 
 
If at any point serious adverse events related to the study protocol occur, these will be reported to the 
principal investigator and thoroughly investigated. The UW IRB has the authority to request that the 
treatment groups be unblinded to ensure there is not overwhelming evidence of harm by the study 
protocol. 
  
Data management 
All patient data will be kept confidential. A unique patient study identification number will be placed on 
the data forms. No patient names will be included with the study data. Study identifiers kept in a 
password protected Excel spreadsheet will be assigned to each patient to protect confidentiality. Patient 
identifiers will be stored separately from the data files on the primary investigator’s password-protected 
computer. Only the study investigators will have access to this identifier list. 
 
Data analysis 


Data will be extracted and entered into SPSS. Analysis will be performed with the blinded data. All above 
listed variables will be analyzed in an intention to treat approach.  
 
The sociodemographic profiles of the two study groups will be compared using descriptive statistics (chi-
squared for nominal data and student’s t-tests for continuous data) to ensure successful randomization. 
Means of continuous variables (satisfaction, pain, age, gestational age) will be compared with a two-sided 
student’s t-test. Data of categorical variables will be compared with a chi-square test. A p-value of <0.05 
defines statistical significance. We will perform subgroup analyses by parity and gestational age, which 
are factors that may affect pain and satisfaction.  
 
Possible Limitations 
Our study population will likely be representative of abortion-seeking clients in Washington state, which 
may be less diverse than the population of abortion-seeking clients throughout the United States. This 
may limit the generalizability of our findings. Additionally, not all clinics throughout the United States 
routinely prescribe oxycodone upon discharge, and thus if we find a reduction in postprocedural opioid 
usage, this may not benefit all clinics.  
 
Timeline 
The study will be conducted at CRC in Renton and Tacoma, Washington. Study procedures will be 
initiated following approval of the protocol by the institutional review boards at University of 
Washington and CRC. We anticipate receiving approval by January 2021.  
 
Given the current volume of first trimester abortion procedures at these sites and enrollment rates in past 
trials at these clinic locations, we anticipate that it will require approximately 12 months to complete 
enrollment. After enrollment, we will have 6 months to complete data analysis or to finish enrollment for 
the study if clinical volume or study participation is low.  
 
Use of Research Results 
The results of this study will be presented during the University of Washington’s Department of 
Obstetrics and Gynecology Resident and Fellow Research Day. They will also be presented to the Society 
of Family Planning community at the Complex Family Planning Fellowship Annual Meeting. Finally, the 
results of this study will be submitted for publication in one of the obstetrics and gynecology specific 
journals. The study will meet criteria to be included in the Cochrane review updates for pain control in 
first trimester abortion.1 


 
Results of this RCT will demonstrate whether or not ketamine is a satisfactory alternative to fentanyl for 
analgesia for first trimester outpatient surgical abortions or management of early pregnancy failures. If it 
is shown to be a satisfactory alternative, this would significantly impact the nation’s opioid crisis as 
clinics could start using ketamine as their standard analgesic rather than fentanyl. We may also find that 
ketamine reduces postoperative opioid use, in which case this will even further impact the nation’s opioid 
crisis and result in less opioid use and addiction related to abortion care. Due to its unique mechanism, 
ketamine may also be an important alternative for patients with substance use disorders, specifically 
opioid use disorders. There has also been interest in IM and intranasal (IN) ketamine, and this study 
would guide future investigations into alternative forms of ketamine to be used in lower resource 
outpatient settings who do not have the ability to have IV access. Results of our study will potentially 
guide the approach to pain management for other outpatient gynecological procedures. 
 
References  
1. Renner RM, Jensen JT, Nichols MD, Edelman AB. "Pain control in first-trimester surgical 
abortion: a systematic review of randomized controlled trials." Contraception 81.5 (2010): 372-
88. 
2. White KO, Jones HE, Lavelanet A, Norman WV, Guilbert E, Lichtenberg ES, et al. "First-
trimester aspiration abortion practices: a survey of United States abortion providers." 
Contraception 99.1 (2019): 10-5. 
3. Ndubisi C, Danvers A, Gold MA, Morrow L, Westhoff CL. "Auricular acupuncture as an adjunct 
for pain management during first trimester abortion: a randomized, double-blinded, three arm 
trial." Contraception 99.3 (2019): 143-7. 
4. Rawling MJ, Wiebe ER. "A randomized controlled trial of fentanyl for abortion pain." American 
Journal of Obstetrics and Gynecology 185.1 (2001): 103-7. 
5. Rosenbaum SB, Gupta V, Palacios JL. "Ketamine." StatPearls (2020): 
https://www.ncbi.nlm.nih.gov/books/NBK470357. 
6. Sultana A, Torres D, Schumann R. "Special indications for opioid free anesthesia and analgesia, 
patient and procedure related: including obesity, sleep apnea, chronic obstructive pulmonary 
disease, complex regional pain syndromes, opioid addiction and cancer surgery." Best Pract Res 
Clin Anesthesiol 31.4 (2017): 547-60. 
7. Shimonovich S, Gigi R, Shapira A, et al. "Intranasal ketamine for acute traumatic pain in the 
emergency department: a prospective, randomized clinical trial of efficacy and safety." BMC 
Emerg Med 16.1 (2016): 43. 


8. Palm N, Floroff C, Hassig TB, Boylan A, Kanter J. "Low-dose ketamine infusion for adjunct 
management during vaso-occlusive episodes in adults with sickle cell disease: a case series." J 
Pain Palliat Care Pharmacother 32.1 (2018): 20-6. 
9. Page N, Nirabhawane V. "Intranasal ketamine for the management of incidental pain during 
wound dressing in cancer patients: a pilot study." Indian J Palliat Care 24.1 (2018): 58-60. 
10. Willeford A, Atayee RS, Winters KD, Mesarwi P. "The enigma of low-dose ketamine for 
treatment of opioid-induced hyperalgesia in the setting of psychosocial suffering and cancer-
associated pain." Journal of Pain & Palliative Care Pharmacotherapy 32.4 (2018): 248-55. 
11. Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, Bhatia A, Davis 
FN, Hooten WM, Cohen SP. "Consensus Guidelines on the Use of Intravenous Ketamine 
Infusions for Acute Pain Management From the American Society Regional Anesthesia and Pain 
Medicine, the American Academy of Pain Medicine, and the American Society of 
Anesthesiologists." Reg Anesth Pain Med 43.5 (2018): 456-466. 
12. Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK, Beach ML. 
"Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients 
with chronic back pain undergoing back surgery." Anesthesiology 113.3 (2010). 
13. Landau R. "Post-cesarean delivery pain." Int J Obstet Anesth 39 (2019): 105-116. 
14. Gao M, Rejaei D, Liu H. "Ketamine use in current clinical practice." Acta Pharmacol Sin 37.7 
(2016): 865-72. 
15. Almeida VT, Molina A. "Comparative study of midazolam with ketamine S(+) versus midazolam 
with uterine paracervical block for manual intrauterine aspiration." Rev Bras Anestesiol 56.5 
(2006): 443-53. 
16. Arikan M, Aslan B, Arikan O, But A, Horasanli E. "Comparison of propofol-remifentanil and 
propofol-ketamine combination for dilation and curettage: a randomized double blind prospective 
trial." Eur Rev Med Pharmacol Sci 19.18 (2015): 3522-7. 
17. Hervey WH, Hustead RF. "Ketamine for dilation and curettage procedures: patient acceptance." 
Anesth Analg 51.4 (1972): 647-55. 
18. Strayer RJ, Nelson LS. "Adverse events associated with ketamine for procedural sedation in 
adults." Am J Emerg Med 26.9 (2008): 985-1028. 
19. Intravenous ketamine for pain control during first trimester surgical abortion. 18 May 2018. 
<ichgcp.n et/clinical-trials-registry/NCT03751423>. 
20. Dexter F, Aker J, Wright WA. "Development of a measure of patient satisfaction with monitored 
anesthesia care: the Iowa Satisfaction with Anesthesia Scale." Anesthesiology 87.4 (1997): 865-
73. 


21. Leake PA, Toppin P, Reid M, et al. "Improving patient outcomes with inguinal hernioplasty-local 
anesthesia versus local anesthesia and conscious sedation: a randomized controlled trial." Hernia 
23.3 (2019): 561-7. 
22. Ramos-Matos CF, Bistas KG, Lopez-Ojeda W. "Fentanyl." StatPearls (2020): April. 
23. Bayer LL, Edelman AB, Fu R, Lambert WE, Nichols MD, Bednarek PH, Miller K, Jensen JT. 
“An Evaluation of Oral Midazolam for Anxiety and Pain in First-Trimester Surgical Abortion: A 
Randomized Controlled Trial.” Obstet Gynecol 126.1 (2015): 37-46.